Last reviewed · How we verify
C14-tozadenant capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
C14-tozadenant capsule (C14-tozadenant capsule) — Biotie Therapies Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| C14-tozadenant capsule TARGET | C14-tozadenant capsule | Biotie Therapies Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- C14-tozadenant capsule CI watch — RSS
- C14-tozadenant capsule CI watch — Atom
- C14-tozadenant capsule CI watch — JSON
- C14-tozadenant capsule alone — RSS
Cite this brief
Drug Landscape (2026). C14-tozadenant capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/c14-tozadenant-capsule. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab